Traders purchased shares of Eli Lilly and Co (NYSE:LLY) on weakness during trading on Friday. $108.99 million flowed into the stock on the tick-up and $42.01 million flowed out of the stock on the tick-down, for a money net flow of $66.98 million into the stock. Of all stocks tracked, Eli Lilly and had the 23rd highest net in-flow for the day. Eli Lilly and traded down ($1.77) for the day and closed at $74.76
A number of brokerages have weighed in on LLY. Goldman Sachs downgraded Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $86.98 to $95.00 in a report on Tuesday, January 16th. Jefferies Group set a $100.00 price objective on Eli Lilly and and gave the company a “buy” rating in a research note on Tuesday, January 16th. Credit Suisse Group reissued a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, December 12th. Finally, Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and raised their price objective for the company from $85.52 to $115.00 in a research note on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $93.37.
The company has a market cap of $85,719.58, a PE ratio of -373.78, a PEG ratio of 1.43 and a beta of 0.28. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.01 and a current ratio of 1.32.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. The company had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. Eli Lilly and’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.95 earnings per share. equities research analysts forecast that Eli Lilly and Co will post 4.87 EPS for the current year.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $81.09, for a total value of $72,981.00. Following the transaction, the insider now owns 4,130 shares of the company’s stock, valued at $334,901.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Donald A. Zakrowski sold 860 shares of the business’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $76.50, for a total value of $65,790.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,261 shares of company stock worth $1,225,085. 0.20% of the stock is owned by insiders.
A number of hedge funds have recently bought and sold shares of the business. Princeton Portfolio Strategies Group LLC boosted its position in Eli Lilly and by 0.3% in the second quarter. Princeton Portfolio Strategies Group LLC now owns 17,860 shares of the company’s stock worth $1,470,000 after purchasing an additional 53 shares during the last quarter. Keel Point LLC boosted its position in Eli Lilly and by 2.6% in the second quarter. Keel Point LLC now owns 7,765 shares of the company’s stock worth $639,000 after purchasing an additional 200 shares during the last quarter. Intellectus Partners LLC boosted its position in Eli Lilly and by 5.1% in the second quarter. Intellectus Partners LLC now owns 4,458 shares of the company’s stock worth $367,000 after purchasing an additional 216 shares during the last quarter. Cypress Capital Management LLC boosted its position in Eli Lilly and by 3.0% in the second quarter. Cypress Capital Management LLC now owns 7,974 shares of the company’s stock worth $656,000 after purchasing an additional 229 shares during the last quarter. Finally, Rowland & Co. Investment Counsel ADV boosted its position in Eli Lilly and by 0.7% in the second quarter. Rowland & Co. Investment Counsel ADV now owns 45,071 shares of the company’s stock worth $3,711,000 after purchasing an additional 309 shares during the last quarter. 77.62% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Traders Buy Shares of Eli Lilly and (LLY) on Weakness” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/03/23/traders-buy-shares-of-eli-lilly-and-lly-on-weakness.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.